{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T14:32:35Z","timestamp":1778509955281,"version":"3.51.4"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81670569"],"award-info":[{"award-number":["81670569"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81570560"],"award-info":[{"award-number":["81570560"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","award":["2018ZX10205504-001-002"],"award-info":[{"award-number":["2018ZX10205504-001-002"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","award":["2014ZX10005001"],"award-info":[{"award-number":["2014ZX10005001"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.antiviral.2020.104953","type":"journal-article","created":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T13:08:45Z","timestamp":1602594525000},"page":"104953","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Anti-viral effect in chronic hepatitis B patients with normal or mildly elevated alanine aminotransferase"],"prefix":"10.1016","volume":"184","author":[{"given":"Qingqing","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kehui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yezhou","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shike","family":"Lou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gangde","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yueqiu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6687-3846","authenticated-orcid":false,"given":"Shisan","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1440-8942","authenticated-orcid":false,"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8550","key":"10.1016\/j.antiviral.2020.104953_bib1","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S0140-6736(87)92735-8","article-title":"Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection","volume":"2","author":"Alexander","year":"1987","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.antiviral.2020.104953_bib2","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/hep.510240201","article-title":"An algorithm for the grading of activity in chronic hepatitis C. The METAVIR","volume":"24","author":"B","year":"1996","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.antiviral.2020.104953_bib3","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJM200102153440706","article-title":"Liver biopsy","volume":"344","author":"Bravo","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.antiviral.2020.104953_bib4","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.cgh.2016.01.019","article-title":"Repeated measurements of hepatitis B surface antigen identify carriers of inactive HBV during long-term follow-up","volume":"14","author":"Brouwer","year":"2016","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.antiviral.2020.104953_bib5","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/infdis\/jir283","article-title":"Viral determinants of hepatitis B surface antigen seroclearance in hepatitis B e antigen-negative chronic hepatitis B patients","volume":"204","author":"Chan","year":"2011","journal-title":"J. Infect. Dis."},{"issue":"3","key":"10.1016\/j.antiviral.2020.104953_bib6","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/hep.510300313","article-title":"Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group","volume":"30","author":"Chien","year":"1999","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.antiviral.2020.104953_bib7","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/jvh.12034","article-title":"Histological improvement of long-term antiviral therapy in chronic hepatitis B patients with persistently normal alanine aminotransferase levels","volume":"20","author":"Du","year":"2013","journal-title":"J. Viral Hepat."},{"issue":"1","key":"10.1016\/j.antiviral.2020.104953_bib8","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2015.04.006","article-title":"Asociacion Latinoamericana para el Estudio del H. EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis","volume":"63","author":"European Association for Study of","year":"2015","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.antiviral.2020.104953_bib9","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"Electronic address eee, European association for the study of the L. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.antiviral.2020.104953_bib10","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jhep.2007.11.011","article-title":"Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors","volume":"48","author":"Fattovich","year":"2008","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.antiviral.2020.104953_bib11","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/hep.21811","article-title":"Hepatitis B virus DNA prediction rules for hepatitis B e antigen-negative chronic hepatitis B","volume":"46","author":"Feld","year":"2007","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.antiviral.2020.104953_bib12","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study","volume":"3","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.antiviral.2020.104953_bib13","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/MCG.0b013e3181f312f5","article-title":"A proposed, evidence-based approach to the treatment of chronic Hepatitis B","volume":"45","author":"Han","year":"2011","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.antiviral.2020.104953_bib14","unstructured":"JD J, JL H, L W, H Z. - Highlights of the Guidelines of Prevention and Treatment for Chronic Hepatitis B. D - 9710009. (- 1007-3418 (Print)):- 21-23."},{"key":"10.1016\/j.antiviral.2020.104953_bib15","unstructured":"JH K, NH W, PJ C, MY L, DS C. - Hepatitis B Genotypes and the Response to Interferon Therapy. D - 8503886. (- 0168-8278 (Print)):- 998-1002."},{"issue":"5","key":"10.1016\/j.antiviral.2020.104953_bib16","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/hep.1840010511","article-title":"Formulation and application of a numerical scoring system for assessing histological","volume":"1","author":"K","year":"1981","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.antiviral.2020.104953_bib17","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1053\/j.gastro.2008.02.075","article-title":"Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT","volume":"134","author":"Kumar","year":"2008","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.antiviral.2020.104953_bib18","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jhep.2007.07.022","article-title":"The clinical significance of persistently normal ALT in chronic hepatitis B infection","volume":"47","author":"Lai","year":"2007","journal-title":"J. Hepatol."},{"issue":"21","key":"10.1016\/j.antiviral.2020.104953_bib19","doi-asserted-by":"crossref","first-page":"6684","DOI":"10.3748\/wjg.v21.i21.6684","article-title":"Hepatitis B virus genotypes and genome characteristics in China","volume":"21","author":"Li","year":"2015","journal-title":"World J. Gastroenterol."},{"issue":"5","key":"10.1016\/j.antiviral.2020.104953_bib20","doi-asserted-by":"crossref","first-page":"559","DOI":"10.4103\/0366-6999.200554","article-title":"Kinetics of hepatitis B surface antigen level in chronic hepatitis B patients who achieved hepatitis B surface antigen loss during pegylated interferon alpha-2a treatment","volume":"130","author":"Li","year":"2017","journal-title":"Chin. Med. J."},{"issue":"5","key":"10.1016\/j.antiviral.2020.104953_bib21","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/hep.24555","article-title":"Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C","volume":"54","author":"Liaw","year":"2011","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.antiviral.2020.104953_bib22","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.jhep.2012.12.006","article-title":"A predictive scoring system for the seroclearance of HBsAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection","volume":"58","author":"Liu","year":"2013","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.antiviral.2020.104953_bib23","doi-asserted-by":"crossref","first-page":"888","DOI":"10.5604\/01.3001.0010.5279","article-title":"Clinical Analysis of Polyethylene Glycol Interferon-alpha Treatment in 155 Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) Patients","volume":"16","author":"Luo","year":"2017","journal-title":"Ann. Hepatol."},{"issue":"5","key":"10.1016\/j.antiviral.2020.104953_bib24","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/0016-5085(90)91167-5","article-title":"A 21-year experience with major hemorrhage after percutaneous liver biopsy","volume":"99","author":"McGill","year":"1990","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.antiviral.2020.104953_bib25","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jhep.2012.04.037","article-title":"Long-term continuous entecavir therapy in nucleos(t)ide-naive chronic hepatitis B patients","volume":"57","author":"Ono","year":"2012","journal-title":"J. Hepatol."},{"issue":"5589","key":"10.1016\/j.antiviral.2020.104953_bib26","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1126\/science.1076813","article-title":"Ecology and evolution. Sex differences in mortality rate","volume":"297","author":"Owens","year":"2002","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.antiviral.2020.104953_bib27","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1053\/gast.2001.22461","article-title":"Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease","volume":"120","author":"Perrillo","year":"2001","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.antiviral.2020.104953_bib28","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1056\/NEJM199008023230503","article-title":"A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group","volume":"323","author":"Perrillo","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2020.104953_bib29","first-page":"453","article-title":"The interferon system in acute and chronic viral hepatitis","volume":"8","author":"Peters","year":"1986","journal-title":"Prog. Liver Dis."},{"issue":"3","key":"10.1016\/j.antiviral.2020.104953_bib30","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jhep.2010.07.046","article-title":"Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir","volume":"54","author":"Reijnders","year":"2011","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.antiviral.2020.104953_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol. Int."},{"issue":"15","key":"10.1016\/j.antiviral.2020.104953_bib32","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1056\/NEJM197504102921503","article-title":"Vertical transmission of hepatitis B antigen in Taiwan","volume":"292","author":"Stevens","year":"1975","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.antiviral.2020.104953_bib33","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1111\/liv.13432","article-title":"Hepatitis B s antigen kinetics during treatment with nucleos(t)ides analogues in patients with hepatitis B e antigen-negative chronic hepatitis B","volume":"37","author":"Striki","year":"2017","journal-title":"Liver Int."},{"issue":"6","key":"10.1016\/j.antiviral.2020.104953_bib34","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1002\/hep.22878","article-title":"Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time","volume":"49","author":"Tai","year":"2009","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.antiviral.2020.104953_bib35","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.antiviral.2020.104953_bib36","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1007\/s10620-011-1841-5","article-title":"The management of chronic hepatitis B in Asian Americans","volume":"56","author":"Tong","year":"2011","journal-title":"Dig. Dis. Sci."},{"issue":"5","key":"10.1016\/j.antiviral.2020.104953_bib37","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.cgh.2008.02.037","article-title":"Significant prevalence of histologic disease in patients with chronic hepatitis B and mildly elevated serum alanine aminotransferase levels","volume":"6","author":"Tsang","year":"2008","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.antiviral.2020.104953_bib38","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1053\/j.gastro.2011.04.046","article-title":"Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters","volume":"141","author":"Tseng","year":"2011","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.antiviral.2020.104953_bib39","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1097\/00007890-199305000-00029","article-title":"Liver biopsy. Its safety and complications as seen at a liver transplant center","volume":"55","author":"Van Thiel","year":"1993","journal-title":"Transplantation"},{"key":"10.1016\/j.antiviral.2020.104953_bib40","unstructured":"CT W, CJ C, M H, AS L. - HBV Genotype B Is Associated with Better Response to Interferon Therapy in HBeAg(+). D - 8302946. (- 0270-9139 (Print)):- 1425-1430."},{"issue":"6","key":"10.1016\/j.antiviral.2020.104953_bib41","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/j.1478-3231.2006.01287.x","article-title":"Non-invasive models for predicting histology in patients with chronic hepatitis B","volume":"26","author":"Wai","year":"2006","journal-title":"Liver Int."},{"issue":"4","key":"10.1016\/j.antiviral.2020.104953_bib42","first-page":"308","article-title":"[Interruption of the transmission of hepatitis B virus from mother to babies]","volume":"10","author":"Wang","year":"2002","journal-title":"Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chin. J. Hepatol."},{"issue":"4","key":"10.1016\/j.antiviral.2020.104953_bib43","first-page":"195","article-title":"A semiquantitative scoring system for assessment of hepatic inflammation and fibrosis in chronic viral hepatitis","volume":"6","author":"Wang","year":"1998","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"issue":"11","key":"10.1016\/j.antiviral.2020.104953_bib44","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1093\/oxfordjournals.aje.a009060","article-title":"Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers","volume":"145","author":"Yu","year":"1997","journal-title":"Am. J. Epidemiol."},{"issue":"3","key":"10.1016\/j.antiviral.2020.104953_bib45","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/infdis\/jir282","article-title":"Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss","volume":"204","author":"Zoutendijk","year":"2011","journal-title":"J. Infect. Dis."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354220303673?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354220303673?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T13:38:58Z","timestamp":1778506738000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354220303673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":45,"alternative-id":["S0166354220303673"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2020.104953","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-viral effect in chronic hepatitis B patients with normal or mildly elevated alanine aminotransferase","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2020.104953","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104953"}}